Dr. Reddy's Laboratories Limited has announced that certain batches of semaglutide were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the product. The company is currently investigating the root cause and implementing appropriate measures to ensure product quality. Consequently, commercial supplies of the product will be delayed for a period until the issue is resolved. Dr. Reddy's has emphasized that there is no impact on patient safety or the product's existing global regulatory filings. The company remains committed to ensuring reliable global supplies of this important metabolic therapy. To discuss this matter and address any participant questions, the management of Dr. Reddy's will host a conference call on Thursday, July 9, 2026, from 16:30 to 17:00 IST (07:00 – 07:30 ET). Participants can pre-register for the call using the provided link. The audio link and transcript will be made available on the company's website.
